Articles related to SMALL CELL LUNG CANCER (SCLC)

“Second-line therapy should not be dismissed outright in platinum-refractory or early-relapsing disease. It remains a relevant part of comprehensive care.” — Tingting Tan, MD, PhD, City of Hope

Global phase 3 study randomized patients with platinum-refractory extensive-stage SCLC to first-in-class bispecific immunotherapy versus regional standard chemotherapy, achieving primary overall survival endpoint with consistent safety profile.

Durvalumab consolidation therapy demonstrated unprecedented survival benefit in limited-stage SCLC, extending median overall survival by nearly two years compared to placebo.

This review encompasses nine recent studies in oncology, highlighting the application of innovative therapies and drug combinations in the treatment of lung cancer.

The phase 3 EXTENTORCH trial has demonstrated the potential of toripalimab plus chemotherapy as a new standard first-line therapy for ES-SCLC, with a median progression-free survival of 5.8 months.

Explore how high-dose hyperfractionated thoracic radiotherapy is setting new standards in LS-SCLC treatment.